Search

CN-121971559-A - Anti-herpes simplex virus traditional Chinese medicine extract and preparation method and application thereof

CN121971559ACN 121971559 ACN121971559 ACN 121971559ACN-121971559-A

Abstract

The invention discloses an anti-herpes simplex virus traditional Chinese medicine extract, a preparation method and application thereof, and relates to the technical field of biological medicines. The invention adopts traditional Chinese herbal medicines as raw materials, innovatively combines water decoction and alcohol precipitation technology to obtain the drug effect part with unique activity in the lophatherum gracile, and the safe and low-toxicity lophatherum gracile extract with anti-herpes virus effect is discovered initially. The nucleoside drugs commonly used in clinic at present have the problems of obvious side effect, easy drug resistance, easy rebound after drug withdrawal and the like, and can not block the virus infection process. The invention provides a new choice for human prevention and treatment of herpes virus infection.

Inventors

  • ZHANG PINGHU
  • LIU SITONG
  • QI LIANWEN
  • LI SAINAN
  • HUANG FENGQING

Assignees

  • 扬州大学

Dates

Publication Date
20260505
Application Date
20251219

Claims (11)

  1. 1. The anti-herpes simplex virus traditional Chinese medicine extract is characterized by being lophatherum gracile extract.
  2. 2. The anti-herpes simplex virus traditional Chinese medicine extract according to claim 1, wherein the lophatherum gracile extract comprises lophatherum gracile water extract and/or lophatherum gracile water extract and alcohol precipitation extract dry material.
  3. 3. The anti-herpes simplex virus traditional Chinese medicine extract according to claim 1, wherein the anti-herpes simplex virus traditional Chinese medicine extract is used for inhibiting replication of herpes simplex virus and/or preventing cytopathy caused by herpes simplex virus infection.
  4. 4. A method for preparing the anti-herpes simplex virus traditional Chinese medicine extract according to any one of claims 1-3, comprising the following steps: soaking herba Lophatheri decoction pieces in water; decocting and filtering the soaked lophatherum gracile decoction pieces to obtain first filter residues and first filtrate; Soaking the first filter residue in water and then decocting to obtain a second filtrate; Uniformly mixing the first filtrate and the second filtrate, centrifuging, filtering and evaporating to obtain a lophatherum gracile water extract, wherein the density of the lophatherum gracile water extract is 0.8-1.5 g/mL; and adding absolute ethyl alcohol into the lophatherum gracile water extract to ensure that the final concentration of the ethyl alcohol is 30-75%, standing to generate precipitate, and carrying out centrifugal separation to obtain the lophatherum gracile water extract and alcohol precipitation extract dry material.
  5. 5. The method for preparing the anti-herpes simplex virus traditional Chinese medicine extract according to claim 4, wherein the volume ratio of the lophatherum gracile decoction pieces to the water is 1 g:10-100 mL.
  6. 6. The method for preparing an anti-herpes simplex virus Chinese medicinal extract according to claim 4, wherein absolute ethanol with the alcohol content of 30%, 50% or 75% is added into the lophatherum gracile water extract.
  7. 7. The method for preparing the anti-herpes simplex virus traditional Chinese medicine extract according to claim 4, wherein the step of decocting the soaked lophatherum gracile decoction pieces comprises the steps of boiling the soaked lophatherum gracile decoction pieces with strong fire and then decocting the same with slow fire for 20-120 minutes.
  8. 8. The method for preparing an anti-herpes simplex virus Chinese medicinal extract according to claim 4, wherein absolute ethyl alcohol is added into the lophatherum gracile water extract, and the mixture is left to stand for 4-72 hours at 4-37 ℃ to generate a precipitate.
  9. 9. The use of an anti-herpes simplex virus traditional Chinese medicine extract according to any one of claims 1-3, wherein the anti-herpes simplex virus traditional Chinese medicine extract is used for preparing a medicament for preventing and treating herpes simplex virus infection.
  10. 10. The use of an anti-herpes simplex virus herbal extract according to claim 9, wherein the medicament further comprises excipients.
  11. 11. The use of an anti-herpes simplex virus Chinese medicinal extract according to claim 9, wherein the medicament is in the form of a tablet, a hydrogel, a pill, a powder, a capsule, an ointment, a granule, an injection or an oral liquid.

Description

Anti-herpes simplex virus traditional Chinese medicine extract and preparation method and application thereof Technical Field The invention relates to the technical field of biological medicines, in particular to an anti-herpes simplex virus traditional Chinese medicine extract and a preparation method and application thereof. Background Herpes is a common type of viral infection caused by the herpes virus (Herpesviruses) and is predominantly manifested by clustered blisters on the skin or mucous membranes, which can occur repeatedly. The herpesvirus is a DNA virus with genome size of 125-230 kbp and encodes about 80-180 viral proteins. It has now been found that there are 100 or more herpesviruses, of which there are three subfamilies α, β, γ, only 8 of which can infect humans and cause skin, mucous membranes and nervous tissue to be affected differently. Herpes viruses associated with human infection are human herpes viruses (Human herpes virus, HHV), commonly referred to as herpes simplex virus type 1 (HSV-1), which primarily cause herpes labialis (e.g., as "flaming" blisters) and may also infect the genitalia, herpes simplex virus type 2 (HSV-2), which primarily cause genital herpes and are transmitted by sexual contact, varicella-zoster virus (VZV), which initially causes varicella and appears as herpes zoster (painful rash) upon recurrence, and others which are human herpes virus types 6 and 7 (which may infect and harbor in various tissues), human herpes virus type 8 (which infects and harbor in lymphocytes), EB virus (infectious mononucleosis), and Cytomegalovirus (CMV), among others. In addition, monkey herpesvirus B can be used as animal-derived virus, and can also infect human, and can cause nervous system infection such as poliomyelitis and encephalitis of human, and the death rate can reach 80%. Among them, herpes simplex virus (Herpes simplex virus, HSV) is a highly infectious virus worldwide, and the viral particles are spherical, and the whole virus consists of DNA genome, capsid, envelope and envelope containing viral glycoprotein. The capsid is icosahedral symmetric and consists of 162 shell particles. The diameter of the virus particles is 150-200 nm, and the virus particles comprise two serotypes of HSV-1 and HSV-2. At present, about 1.4 hundred million people are infected with HSV-1 and 5 hundred million people are infected with HSV-2 every year, the number of cases is in an increasing trend year by year, and the risk of acquiring and transmitting HIV infection is increased by infecting type 2 herpes simplex virus. HSV is transmitted mainly through respiratory tract, skin, mucous membrane and sexual contact, causing clinical symptoms such as gingivitis, herpes labialis, herpetic keratoconjunctivitis, encephalitis, genital herpes and neonatal herpes. It is notable that herpes simplex virus cannot be cured radically because of its characteristic of long-term latency, recurrent attacks and neurotropic tissue, is not cleared once infected, is carried throughout the life, and is also infectious, and can spread even during asymptomatic periods (asymptomatic detoxification). Prophylactic vaccines against HSV are also designed for prophylactic use, essentially at an early stage, like BNT163 and delta gD-2, and entered phase I clinic in 2024. The current state of Thyreos R2, developed by Thyreos lnc Thyreos, was also only in preclinical studies. While therapeutic vaccines against HSV currently progress a little more, the fastest one is the mRNA-1608 of Moderna, which is about to complete phase II clinical, no HSV vaccine has yet been successfully marketed. At present, the medicaments for herpes simplex only comprise nucleoside-type lovir and derivatives such as antiviral medicaments of acyclovir, valacyclovir, famciclovir and the like. The medicine can shorten the course of disease and reduce relapse (needing to be used in early stage) by inhibiting viral DNA polymerase to block viral replication, but has certain toxic and side effects at the same time, and can possibly cause anaphylactic reaction, so that headache, ataxia and gastrointestinal discomfort are caused, and the risk of acute kidney injury is caused and drug resistance is easily caused after long-term use. People with immunodeficiency such as HIV infected person and organ transplantation recipient with low immunity have obviously increased incidence rate of HSV infection, more serious clinical manifestation, and easy occurrence of chronic ulcer and disseminated infection. HSV can target the cGAS-STING signaling pathway through a multi-level mechanism to escape host antiviral immunity. In addition to UL38 found by the Ren Yujie/Zhou Xi （Wang A ,Peng Q ,Fan H , et al. Herpes simplex virus 1 encodes a STING antagonist that can be therapeutically targeted. [J]. Cell reports. Medicine, 2025, 6 (4): 102051.） team study as a direct STING antagonist, they also found that HSV-1 encoded ICP27, UL46, etc. proteins could each target other host p